LT2785374T - Gallid herpesvirus 3 (mdv serotipo 2) rekombinantiniai vektoriai, ekspresuojantys paukščių patogenų antigenus, ir jų panaudojimas - Google Patents

Gallid herpesvirus 3 (mdv serotipo 2) rekombinantiniai vektoriai, ekspresuojantys paukščių patogenų antigenus, ir jų panaudojimas

Info

Publication number: LT2785374T
Authority: LT; Lithuania
Prior art keywords: vectors expressing; expressing antigens; avian pathogens; gallid herpesvirus; recombinant gallid
Prior art date: 2011-11-30

Application number

LTEP12805843.5T

Other languages

English (en)

Inventor

Michel Bublot

Teshome Mebatsion

Joyce Pritchard

Perry LINZ

Original Assignee

Merial, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-11-30

Filing date

2012-11-29

Publication date

2019-04-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47358292&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2785374(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-11-29 Application filed by Merial, Inc. filed Critical Merial, Inc.

2019-04-25 Publication of LT2785374T publication Critical patent/LT2785374T/lt

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/869—Herpesviral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/17—Newcastle disease virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/255—Marek's disease virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
- C07K14/125—Newcastle disease virus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/14—Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16041—Use of virus, viral particle or viral elements as a vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16041—Use of virus, viral particle or viral elements as a vector
- C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16071—Demonstrated in vivo effect
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
- C12N2710/16341—Use of virus, viral particle or viral elements as a vector
- C12N2710/16343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Virology (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Microbiology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Mycology (AREA)
Biotechnology (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Communicable Diseases (AREA)
General Chemical & Material Sciences (AREA)
Pulmonology (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
Tropical Medicine & Parasitology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)

LTEP12805843.5T 2011-11-30 2012-11-29 Gallid herpesvirus 3 (mdv serotipo 2) rekombinantiniai vektoriai, ekspresuojantys paukščių patogenų antigenus, ir jų panaudojimas LT2785374T (lt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161564877P	2011-11-30	2011-11-30
US201261694957P	2012-08-30	2012-08-30
PCT/US2012/067123 WO2013082317A2 (en)	2011-11-30	2012-11-29	Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof

Publications (1)

Publication Number	Publication Date
LT2785374T true LT2785374T (lt)	2019-04-25

Family

ID=47358292

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
LTEP12801680.5T LT2785373T (lt)	2011-11-30	2012-11-29	Rekombinantiniai hvt vektoriai, ekspresuojantys paukščių patogenų antigenus, ir jų panaudojimas
LTEP17179863.0T LT3251691T (lt)	2011-11-30	2012-11-29	Rekombinantiniai hvt vektoriai, ekspresuojantys paukščių patogenų antigenus, ir jų panaudojimas
LTEP12805843.5T LT2785374T (lt)	2011-11-30	2012-11-29	Gallid herpesvirus 3 (mdv serotipo 2) rekombinantiniai vektoriai, ekspresuojantys paukščių patogenų antigenus, ir jų panaudojimas

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
LTEP12801680.5T LT2785373T (lt)	2011-11-30	2012-11-29	Rekombinantiniai hvt vektoriai, ekspresuojantys paukščių patogenų antigenus, ir jų panaudojimas
LTEP17179863.0T LT3251691T (lt)	2011-11-30	2012-11-29	Rekombinantiniai hvt vektoriai, ekspresuojantys paukščių patogenų antigenus, ir jų panaudojimas

Country Status (28)

Country	Link
EP (7)	EP3263130A1 (lt)
JP (1)	JP6149301B2 (lt)
KR (1)	KR102013135B1 (lt)
CN (3)	CN104159604B (lt)
AR (2)	AR090401A1 (lt)
BR (1)	BR112014013276B1 (lt)
CA (1)	CA2857025C (lt)
CO (1)	CO7061033A2 (lt)
CY (3)	CY1121528T1 (lt)
DK (3)	DK2785374T3 (lt)
ES (3)	ES2775218T3 (lt)
HK (4)	HK1248566A1 (lt)
HR (3)	HRP20190525T8 (lt)
HU (3)	HUE047724T2 (lt)
IN (1)	IN2014CN04833A (lt)
LT (3)	LT2785373T (lt)
ME (1)	ME03433B (lt)
MX (2)	MX365984B (lt)
PE (1)	PE20141482A1 (lt)
PH (2)	PH12014501174B1 (lt)
PL (3)	PL3251691T3 (lt)
PT (3)	PT3251691T (lt)
RS (3)	RS58610B1 (lt)
RU (1)	RU2620936C2 (lt)
SI (3)	SI3251691T1 (lt)
UA (1)	UA118651C2 (lt)
WO (2)	WO2013082317A2 (lt)
ZA (1)	ZA201403804B (lt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013057236A1 (en)	2011-10-21	2013-04-25	Intervet International B.V.	Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens
EP3263130A1 (en)	2011-11-30	2018-01-03	Merial, Inc.	Recombinant hvt vectors expressing antigens of avian pathogens and uses thereof
EP2644702A1 (en)	2012-03-30	2013-10-02	Ceva Sante Animale	Multivalent recombinant avian herpes virus and vaccine for immunizing avian species
AR097029A1 (es)	2013-07-26	2016-02-17	Intervet Int Bv	Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune
EP2845904A1 (en) *	2013-09-06	2015-03-11	Ceva Sante Animale	Recombinant Marek's disease viruses and uses thereof
AR103245A1 (es) *	2014-12-24	2017-04-26	Intervet Int Bv	Vacuna vectorial basada en hvt (herpes virus de los pavos) frente a nd (enfermedad de newcastle) - ibd (enfermedad de gumboro) mejorada
EP3334833A4 (en) *	2015-08-10	2019-04-24	The Texas A&M University System	RECOMBINANT TURKEY HERPES VIRUS VACCINES AND USES THEREOF
ES2935643T3 (es)	2016-06-17	2023-03-08	Intervet Int Bv	Construcciones de virus de la enfermedad de Marek no patógeno recombinante que codifican antígenos del virus de la laringotraqueítis infecciosa y del virus de la bursitis infecciosa
JOP20190088A1 (ar) *	2016-10-21	2019-04-21	Us Agriculture	نواقل مؤتلفة للتعبير عن مولدات مضاد فيروس انفلونزا الطيور و استخداماتها
EP3744342A1 (en)	2016-12-14	2020-12-02	Boehringer Ingelheim Animal Health USA Inc.	Recombinant hvt vectors expressing multiple antigens of avian pathogens, and vaccines comprising them
CN106929483B (zh) *	2017-01-19	2020-09-25	北京邦卓生物科技有限公司	表达鸡新城疫病毒f基因的重组火鸡疱疹病毒的构建及其应用
CN106701693A (zh) *	2017-01-19	2017-05-24	北京邦卓生物科技有限公司	表达血清ⅰ型马立克氏病病毒gb基因的重组火鸡疱疹病毒的构建及其应用
EP3391903B1 (en) *	2017-04-21	2022-02-23	The Pirbright Institute	Recombinant gallid herpesvirus 3 vaccines encoding heterologous avian pathogen antigens
CN107099513B (zh) *	2017-06-22	2020-07-14	北京邦卓生物科技有限公司	一种共表达ndv hn和ibdv vp2基因的hvt的构建及其应用
CN107254450A (zh) *	2017-07-20	2017-10-17	扬州大学	克服鸡新城疫母源抗体影响的嵌合新城疫病毒疫苗载体候选株及构建方法
CN107603958A (zh) *	2017-09-29	2018-01-19	天津农学院	融合表达TM‑1基因和gD基因重组腺病毒的构建方法及重组腺病毒和应用
MX2020003591A (es) *	2017-10-12	2020-07-22	Intervet Int Bv	Constructos del virus recombinante no patogenico de la enfermedad de marek que codifica multiples antigenos heterologos.
US11291715B2 (en)	2017-12-20	2022-04-05	Intervet Inc.	Diluent for cell-associated alphaherpesvirus vaccine
CN108543067A (zh) *	2017-12-25	2018-09-18	中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心）	共表达h5亚型禽流感ha蛋白和传染性法氏囊vp2蛋白的重组火鸡疱疹病毒疫苗株
WO2019147869A2 (en) *	2018-01-24	2019-08-01	Virogin Biotech Canada Ltd	Recombinant viral vaccines
CN109468315B (zh) *	2018-12-07	2021-09-07	袁隆平农业高科技股份有限公司	水稻耐淹基因Sub1共显性分子标记及应用
JP2022515172A (ja)	2018-12-21	2022-02-17	セヴァサンテアニマレ	複数の外来遺伝子を含む組換えトリヘルペスウイルス
MX2022002994A (es)	2019-09-11	2022-06-14	Zoetis Services Llc	Vectores de herpesvirus de los pavos recombinante que expresan antígenos de patógenos aviares y usos de estos.
CN110872578B (zh) *	2019-11-29	2022-09-16	扬州优邦生物药品有限公司	一株变异株传染性法氏囊病毒、亚单位疫苗及其制备方法和应用
US11299517B2 (en) *	2020-04-15	2022-04-12	The United States Of America, As Represented By The Secretary Of Agriculture	Recombinant vaccine against Marek's disease and Newcastle disease
CN116472057A (zh)	2020-06-17	2023-07-21	勃林格殷格翰动物保健有限公司	表达流感血凝素的重组hvt载体和免疫原性组合物，以及其生产和用途
CN112206317B (zh) *	2020-10-12	2023-09-22	浙江省淡水水产研究所	一种草鱼出血病二价核酸菌蜕疫苗的制备方法
MX2023004358A (es)	2020-10-15	2023-07-25	Ceva Sante Animale	Hvt recombinante y usos de este.
CN114317827B (zh) *	2022-01-07	2023-03-24	河南省农业科学院	一种鉴别不同血清型马立克病病毒感染与免疫的多重pcr引物、方法及应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4769330A (en)	1981-12-24	1988-09-06	Health Research, Incorporated	Modified vaccinia virus and methods for making and using the same
US5174993A (en)	1981-12-24	1992-12-29	Health Research Inc.	Recombinant avipox virus and immunological use thereof
US4722848A (en)	1982-12-08	1988-02-02	Health Research, Incorporated	Method for immunizing animals with synthetically modified vaccinia virus
US4603112A (en)	1981-12-24	1986-07-29	Health Research, Incorporated	Modified vaccinia virus
EP0138854B1 (en)	1983-03-08	1992-11-04	Chiron Mimotopes Pty. Ltd.	Antigenically active amino acid sequences
WO1987004463A1 (en)	1986-01-27	1987-07-30	Syntro Corporation	Attenuated herpesviruses, herpesviruses which include foreign dna encoding an amino acid sequence and vaccine containing same
JP2779447B2 (ja)	1988-03-20	1998-07-23	財団法人阪大微生物病研究会	弱毒マレック病ウイルス・ベクターを用いる組換え遺伝子作成法、及び該ウイルスの組換え体
EP0431668B1 (en)	1989-12-04	1995-02-15	Akzo Nobel N.V.	Recombinant herpesvirus of turkeys and live vector vaccines derived thereof
WO1992015672A1 (en)	1991-03-07	1992-09-17	Virogenetics Corporation	Genetically engineered vaccine strain
BE1004877A3 (fr)	1991-05-27	1993-02-16	Solvay	Virus de l'avipox recombinant, culture de cellules infectees par ce virus et vaccins pour la volaille derives de ce virus.
US5853733A (en)	1993-02-26	1998-12-29	Syntro Corporation	Recombinant herpesvirus of turkeys and uses thereof
US6183753B1 (en)	1994-08-09	2001-02-06	Schering-Plough Veterinary Corp.	Recombinant chimeric virus and uses thereof
FR2719056B1 (fr)	1994-04-20	1996-09-06	Rhone Merieux	Herpesvirus transformés pour exprimer gD in vitro.
ES2360298T3 (es) *	1994-08-09	2011-06-02	Schering-Plough Ltd.	Herpesvirus recombinantes de pavos y sus usos.
RU2059414C1 (ru) *	1994-12-09	1996-05-10	Государственная Курская биофабрика - Фирма "БИОК"	Поливалентная вакцина для профилактики болезни марека и способ ее изготовления
FR2728795B1 (fr)	1994-12-30	1997-03-21	Rhone Merieux	Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
JPH104956A (ja) *	1996-06-21	1998-01-13	Univ Michigan State	マレク病ワクチン製造のための維持可能な細胞株の改良
FR2751225B1 (fr) *	1996-07-19	1998-11-27	Rhone Merieux	Formule de vaccin polynucleotidique aviaire
WO1998016247A1 (en)	1996-10-11	1998-04-23	The Regents Of The University Of California	Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US5980912A (en)	1997-03-25	1999-11-09	Zonagen, Inc.	Chitosan induced immunopotentiation
EP1026246B1 (en) *	1997-10-03	2006-11-29	Zeon Corporation	Avian infectious herpesvirus recombinants and recombinant vaccines prepared with the use of the same
EP0974660A1 (en)	1998-06-19	2000-01-26	Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO)	Newcastle disease virus infectious clones, vaccines and diagnostic assays
US6299882B1 (en)	1999-04-09	2001-10-09	Schering Corporation	UL54.5 of Marek's disease virus (MDV)
KR100354972B1 (ko)	2000-04-11	2002-10-05	대한민국	닭전염성기관지염 바이러스 ｓ1 단백질을 발현하는유전자재조합 마렉바이러스 및 그의 제조방법
US6764684B2 (en) *	2001-09-28	2004-07-20	Zeon Corporation	Avian herpesvirus-based recombinant infectious bursal disease vaccine
US6866852B2 (en) *	2002-01-31	2005-03-15	Zeon Corporation	Recombinant herpesvirus of turkeys and use thereof
KR100801180B1 (ko) *	2006-09-26	2008-02-05	주식회사 고려비엔피	약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신
WO2010119112A1 (en) *	2009-04-15	2010-10-21	Ceva Sante Animale	Recombinant avian herpes virus vectors and vaccine for immunizing waterfowl species
EP3263130A1 (en)	2011-11-30	2018-01-03	Merial, Inc.	Recombinant hvt vectors expressing antigens of avian pathogens and uses thereof

2012
- 2012-11-29 EP EP17181500.4A patent/EP3263130A1/en not_active Ceased
- 2012-11-29 PE PE2014000764A patent/PE20141482A1/es active IP Right Grant
- 2012-11-29 AR ARP120104498A patent/AR090401A1/es active IP Right Grant
- 2012-11-29 HU HUE12801680A patent/HUE047724T2/hu unknown
- 2012-11-29 MX MX2014006360A patent/MX365984B/es active IP Right Grant
- 2012-11-29 LT LTEP12801680.5T patent/LT2785373T/lt unknown
- 2012-11-29 PL PL17179863T patent/PL3251691T3/pl unknown
- 2012-11-29 EP EP22174415.4A patent/EP4112073A1/en active Pending
- 2012-11-29 MX MX2014006361A patent/MX361893B/es active IP Right Grant
- 2012-11-29 EP EP19167407.6A patent/EP3578199A1/en active Pending
- 2012-11-29 HR HRP20190525TT patent/HRP20190525T8/hr unknown
- 2012-11-29 SI SI201231722T patent/SI3251691T1/sl unknown
- 2012-11-29 ME MEP-2019-103A patent/ME03433B/me unknown
- 2012-11-29 KR KR1020147017914A patent/KR102013135B1/ko active IP Right Grant
- 2012-11-29 CN CN201280066323.XA patent/CN104159604B/zh active Active
- 2012-11-29 LT LTEP17179863.0T patent/LT3251691T/lt unknown
- 2012-11-29 SI SI201231721T patent/SI2785373T1/sl unknown
- 2012-11-29 LT LTEP12805843.5T patent/LT2785374T/lt unknown
- 2012-11-29 PL PL12801680T patent/PL2785373T3/pl unknown
- 2012-11-29 EP EP19167408.4A patent/EP3572092A1/en active Pending
- 2012-11-29 CN CN201610341171.XA patent/CN105920598A/zh active Pending
- 2012-11-29 RS RS20190443A patent/RS58610B1/sr unknown
- 2012-11-29 DK DK12805843.5T patent/DK2785374T3/en active
- 2012-11-29 WO PCT/US2012/067123 patent/WO2013082317A2/en active Application Filing
- 2012-11-29 RU RU2014126375A patent/RU2620936C2/ru active
- 2012-11-29 EP EP12801680.5A patent/EP2785373B1/en active Active
- 2012-11-29 ES ES17179863T patent/ES2775218T3/es active Active
- 2012-11-29 CA CA2857025A patent/CA2857025C/en active Active
- 2012-11-29 BR BR112014013276-3A patent/BR112014013276B1/pt active IP Right Grant
- 2012-11-29 SI SI201231570T patent/SI2785374T1/sl unknown
- 2012-11-29 RS RS20200111A patent/RS59892B1/sr unknown
- 2012-11-29 HU HUE17179863A patent/HUE047909T2/hu unknown
- 2012-11-29 UA UAA201407192A patent/UA118651C2/uk unknown
- 2012-11-29 EP EP12805843.5A patent/EP2785374B2/en active Active
- 2012-11-29 PT PT171798630T patent/PT3251691T/pt unknown
- 2012-11-29 DK DK12801680.5T patent/DK2785373T3/da active
- 2012-11-29 RS RS20200113A patent/RS59893B1/sr unknown
- 2012-11-29 WO PCT/US2012/067135 patent/WO2013082327A1/en active Application Filing
- 2012-11-29 IN IN4833CHN2014 patent/IN2014CN04833A/en unknown
- 2012-11-29 HU HUE12805843A patent/HUE042471T2/hu unknown
- 2012-11-29 PL PL12805843.5T patent/PL2785374T5/pl unknown
- 2012-11-29 ES ES12805843T patent/ES2719409T5/es active Active
- 2012-11-29 CN CN201280066324.4A patent/CN104159605B/zh active Active
- 2012-11-29 PT PT128016805T patent/PT2785373T/pt unknown
- 2012-11-29 PT PT12805843T patent/PT2785374T/pt unknown
- 2012-11-29 AR ARP120104499A patent/AR089039A1/es not_active Application Discontinuation
- 2012-11-29 DK DK17179863.0T patent/DK3251691T3/da active
- 2012-11-29 JP JP2014544892A patent/JP6149301B2/ja active Active
- 2012-11-29 ES ES12801680T patent/ES2785045T3/es active Active
- 2012-11-29 EP EP17179863.0A patent/EP3251691B1/en active Active
2014
- 2014-05-23 ZA ZA2014/03804A patent/ZA201403804B/en unknown
- 2014-05-26 PH PH12014501174A patent/PH12014501174B1/en unknown
- 2014-06-24 CO CO14136125A patent/CO7061033A2/es unknown
- 2014-10-21 HK HK18108356.1A patent/HK1248566A1/zh unknown
- 2014-10-21 HK HK18107348.4A patent/HK1247832A1/zh unknown
- 2014-10-21 HK HK14110483A patent/HK1197175A1/xx unknown
2015
- 2015-01-15 HK HK15100455.1A patent/HK1200018A1/xx unknown
- 2015-12-16 PH PH12015502790A patent/PH12015502790B1/en unknown
2019
- 2019-04-09 CY CY20191100394T patent/CY1121528T1/el unknown
- 2019-12-10 HR HRP20192215TT patent/HRP20192215T1/hr unknown
- 2019-12-12 HR HRP20192241TT patent/HRP20192241T1/hr unknown
- 2019-12-16 CY CY20191101319T patent/CY1122872T1/el unknown
2020
- 2020-01-07 CY CY20201100003T patent/CY1124618T1/el unknown

Also Published As

Publication number	Publication date
EP4112073A1 (en)	2023-01-04
HK1200018A1 (en)	2015-07-31
PH12015502790A1 (en)	2017-07-10
MX361893B (es)	2018-12-18
ES2775218T3 (es)	2020-07-24
BR112014013276B1 (pt)	2021-07-27
HRP20192215T1 (hr)	2020-02-21
RU2620936C2 (ru)	2017-05-30
RU2014126375A (ru)	2016-01-27
RS59892B1 (sr)	2020-03-31
CA2857025C (en)	2021-08-03
ES2785045T3 (es)	2020-10-05
CO7061033A2 (es)	2014-09-19
MX2014006360A (es)	2015-03-05
PH12014501174A1 (en)	2014-09-08
MX2014006361A (es)	2015-03-05
BR112014013276A2 (pt)	2018-05-15
AR089039A1 (es)	2014-07-23
HUE047724T2 (hu)	2020-05-28
IN2014CN04833A (lt)	2015-09-18
ME03433B (me)	2020-01-20
HRP20190525T4 (hr)	2023-01-20
EP3263130A1 (en)	2018-01-03
PL2785374T5 (pl)	2023-01-09
EP2785374B2 (en)	2022-08-17
HK1197175A1 (en)	2015-01-09
PT2785373T (pt)	2020-01-27
PL3251691T3 (pl)	2020-06-01
EP2785373A1 (en)	2014-10-08
CN104159605A (zh)	2014-11-19
EP2785374A2 (en)	2014-10-08
KR102013135B1 (ko)	2019-08-22
WO2013082317A2 (en)	2013-06-06
CN104159605B (zh)	2019-04-19
ZA201403804B (en)	2015-04-29
PL2785374T3 (pl)	2019-07-31
PL2785373T3 (pl)	2020-06-01
AR090401A1 (es)	2014-11-12
ES2719409T3 (es)	2019-07-10
KR20140097515A (ko)	2014-08-06
EP3251691B1 (en)	2019-11-20
CN104159604B (zh)	2016-08-24
LT3251691T (lt)	2020-02-10
SI2785373T1 (sl)	2020-02-28
EP3572092A1 (en)	2019-11-27
PH12015502790B1 (en)	2017-07-10
HRP20190525T8 (hr)	2023-01-20
JP2015500806A (ja)	2015-01-08
EP2785373B1 (en)	2019-11-20
ES2719409T5 (es)	2022-12-07
LT2785373T (lt)	2020-02-10
EP3251691A1 (en)	2017-12-06
CN105920598A (zh)	2016-09-07
WO2013082327A8 (en)	2014-07-03
CY1124618T1 (el)	2022-03-24
SI2785374T1 (sl)	2019-04-30
PH12014501174B1 (en)	2014-09-08
PE20141482A1 (es)	2014-11-08
HK1247832A1 (zh)	2018-10-05
UA118651C2 (uk)	2019-02-25
JP6149301B2 (ja)	2017-06-21
RS58610B1 (sr)	2019-05-31
DK2785373T3 (da)	2020-02-03
HK1248566A1 (zh)	2018-10-19
WO2013082317A3 (en)	2013-08-15
CY1122872T1 (el)	2021-05-05
MX365984B (es)	2019-06-21
WO2013082327A1 (en)	2013-06-06
CY1121528T1 (el)	2020-05-29
SI3251691T1 (sl)	2020-02-28
HUE047909T2 (hu)	2020-05-28
DK3251691T3 (da)	2020-02-10
WO2013082317A8 (en)	2014-07-10
DK2785374T3 (en)	2019-04-08
PT3251691T (pt)	2020-01-28
PT2785374T (pt)	2019-05-09
HRP20192241T1 (hr)	2020-03-06
RS59893B1 (sr)	2020-03-31
EP2785374B1 (en)	2019-01-09
CA2857025A1 (en)	2013-06-06
EP3578199A1 (en)	2019-12-11
CN104159604A (zh)	2014-11-19
HUE042471T2 (hu)	2019-07-29
HRP20190525T1 (hr)	2019-05-03

Publication	Publication Date	Title
HK1200018A1 (en)	2015-07-31	Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof 3(mdv 2)
HK1256651A1 (zh)	2019-09-27	重組hcmv和rhcmv載體以及它們的用途
EP2783005A4 (en)	2015-07-22	NEW THERAPEUTIC VECTORS
PL3041939T3 (pl)	2019-12-31	Rekombinowane wirusy choroby mareka i ich zastosowania
HRP20181439T1 (hr)	2018-11-02	Cjepivo protiv modificiranog virusa sendai i vizualizacijski vektor
EP2598636A4 (en)	2014-03-05	VECTORS AND METHODS FOR EXPRESSION OF RECOMBINANT PROTEINS
EP2553105A4 (en)	2013-09-25	COMPOSITIONS AND METHOD FOR PRODUCING RECOMBINANT VIRUS VECTORS
PT3333265T (pt)	2020-05-11	Vectores de hcmv e rhcmv recombinantes codificadores de um antigénio heterólogo isolado a partir do vírus da hepatite b e seus usos